Guangzhou Paizhen Biotechnology
Accelerating gene therapy product development by providing an integrated one-stop solution including plasmid, viral vector, fill-finish and QC analytical services.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor investor investor | €0.0 | round |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| investor investor investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
* | CNY100m | Series C | |
| Total Funding | 000k | ||
Related Content
PackGene is a rapidly growing Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) specializing in recombinant adeno-associated virus (AAV) vector production. The company provides a comprehensive range of services, from research-grade to clinical-grade plasmid DNA and AAV viral vector production. PackGene's proprietary technology platform utilizes the triple plasmid transfection HEK293 cell process, which is central to delivering high purity, high titer, high infectivity, and high yield AAV vectors, capable of producing up to 1E17 vector genomes per batch.
PackGene serves a diverse clientele, including academic institutions, biotechnology firms, and pharmaceutical companies engaged in gene therapy research and development. The company operates in the biopharmaceutical market, focusing on gene therapy applications that require high-quality AAV vectors for preclinical and clinical studies.
The business model is service-based, generating revenue through the provision of AAV vector production services. Clients pay for the production of custom AAV vectors tailored to their specific research and clinical needs. Additionally, PackGene offers quality control assays to ensure the identity, purity, content potency, and safety of the AAV vectors produced.
Keywords: AAV vectors, gene therapy, CRO, CDMO, plasmid DNA, HEK293 cells, high purity, high titer, high infectivity, biopharmaceutical.